Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 27,126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Activity Clear all
Withdrawn Phase 3 Interventional

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

NCT04225299
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD®
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 3:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adaptive Recruitment Curve Analysis Using Bayesian Modeling

NCT07561372
View directory record Official record
Conditions
Modeling of Recruitment Curves
Interventions
Algorithm: Uniform Sampling, Algorithm: hbMEP-adaptive algorithm (version 1), Algorithm: hbMEP-adaptive algorithm (version 2), ML-PEST, MagPro X100 Transcranial Magnetic Stimulation, Digitimer DS8R Transcutaneous Electrical stimulation
Other · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Supervision in Substance Use Disorder Treatment Programs

NCT07262372
View directory record Official record
Conditions
Self Efficacy, Burnout, Professional, Substance Use Disorders, Supervision
Interventions
FOCUS supervision strategy
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise-induced Hypoalgesia After Comparative Forms of Exercise

NCT01883895
View directory record Official record
Conditions
Pain
Interventions
Forgionei-Barber pressure-pain stimulator, Concentric Exercise, isometric exercise
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 1 Interventional

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

NCT00000777
View directory record Official record
Conditions
HIV Infections, Pregnancy, HIV Seronegativity
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 3:14 PM EDT
Not listed Not applicable Interventional

Initial Study of Insomnia/Nightmare Group Treatment for Posttraumatic Stress Disorder (PTSD)

NCT01314612
View directory record Official record
Conditions
Insomnia, Nightmares, Posttraumatic Stress Disorder
Interventions
Cognitive-Behavioral Insomnia and Nightmare Group
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Autonomic Nervous System and Chronic Fatigue Syndrome

NCT00580619
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions
Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

NMDA Receptors in Motor Learning in Humans

NCT02082912
View directory record Official record
Conditions
Stroke
Interventions
D-cycloserine, Placebo, HandMentor Pro
Drug · Other · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 23, 2026, 3:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

NCT00665665
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC 0070-0002-0182, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 23, 2026, 3:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

NCT02216071
View directory record Official record
Conditions
Acute Otitis Externa
Interventions
Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Drug
Lead sponsor
Exela Pharma Sciences, LLC.
Industry
Eligibility
6 Months and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 23, 2026, 3:14 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents

NCT01721109
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
EVG/COBI/FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Oakland, California • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 23, 2026, 3:14 PM EDT
Terminated Not applicable Interventional

High-intensity Interval Training for Obese Individuals

NCT04075799
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
high-intensity interval training
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 23, 2026, 3:14 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development

NCT00401232
View directory record Official record
Conditions
Healthy Subjects
Interventions
Blood Collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
955 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.

NCT00746499
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Raltegravir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Muscle for Functional Independence Trial

NCT01049698
View directory record Official record
Conditions
Obesity
Interventions
Resistance Training, Resistance Training + Diet
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 79 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)

NCT06470763
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ANV600, ANV600 + pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Anaveon AG
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

NCT05731128
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)

NCT00481507
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Kefir, Placebo
Other
Lead sponsor
Georgetown University
Other
Eligibility
1 Year to 5 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 23, 2026, 3:14 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of COMmunity of Practice And Safety Support (COMPASS) for Home Care Workers

NCT02113371
View directory record Official record
Conditions
Wounds and Injuries, Health Promotion
Interventions
Intervention
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 3:14 PM EDT